Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
61 hedge funds and large institutions have $61.4M invested in Agile Therapeutics in 2020 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 11 closing their positions.
250% more call options, than puts
Call options by funds: $1.03M | Put options by funds: $294K
164% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 11
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
33% more funds holding
Funds holding: 46 → 61 (+15)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less capital invested
Capital invested by funds: $68.1M → $61.4M (-$6.62M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$11.5M |
| 2 |
Millennium Management
New York
|
+$3.68M |
| 3 |
O
OrbiMed
New York
|
+$3.44M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.28M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$6.53M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.22M |
| 3 |
EP
Eversept Partners
New York
|
-$1.22M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$819K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$350K |
AGRX Hedge Fund Activity: Q1 2020 in Review
61 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q1 2020, worth a combined $61.4M — down 9.7% from $68.1M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new AGRX positions and 11 closed out — a net gain of 18 holders — while 17 added to existing stakes and 10 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $11.5M. The largest seller was Renaissance Technologies, cutting an estimated $6.53M.
- 61 institutional investors held Agile Therapeutics (AGRX) as of Q1 2020, up from 46 in Q4 2019.
- Funds reported $61.4M of Agile Therapeutics stock for Q1 2020, down 9.7% quarter-over-quarter.
- 29 funds opened new Agile Therapeutics positions in Q1 2020 and 11 closed out, a net change of +18 holders.
- The largest Agile Therapeutics buyer in Q1 2020 was Perceptive Advisors, an estimated $11.5M added.
- The largest Agile Therapeutics seller in Q1 2020 was Renaissance Technologies, an estimated $6.53M sold.
Based on aggregated 13F filings for Q1 2020.